A whole-body MRI (WB-MRI) including T1, short time inversion recovery (STIR), diffusion-weighted imaging (high b value) was applied in our center for the detection of bone metastasis in prostate cancer (PCa) patients. We intended to assess the diagnostic performance of this examination.
547 cases of PCa patients with higher risk of metastasis were referred to bone scintigraphy with SPECT/CT (BS + SPECT/CT) and whole-body MRI in Shanghai Changhai Hospital. Best valuable comparator (BVC) was applied for the final diagnosis of metastasis. A panel of radiologists interpreted the results. Decision curve analysis (DCA) and receiver operating characteristic curve (ROC) analysis were applied.
Bone metastasis was diagnosed in 110 cases, and others were non-metastatic by BVC. The area under the receiver operating characteristic curve (AUC) was higher in WB-MRI (0.778) than BS + SPECT/CT (0.634, p < 0.001). A WB-MRI-based prediction model was established with AUC of 0.877. Internal validation showed that the predictive model was well-calibrated. The DCA demonstrated that the model had higher net benefit than the BS + SPECT/CT-based model.
WB-MRI is more effective in identifying metastasis in PCa patients than BS + SPECT/CT. The prediction model combined WB-MRI with clinical parameters may be a promising approach to the assessment of metastasis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D’Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S (2016) Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 17(6):727–737
Marc Z, Zelefsky MJ, Higano CS, Carroll PR (2008) Conventional treatments of localized prostate cancer. Urology 72(6):S25–S35
Lecouvet FE, Daphné G, Annabelle S, François J, Jacques J, Bertrand Janne DO, Patrick T, Bruno VB, Bertrand T (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25(22):3281–3287
Behnaz G, Riwa K, Shuhei K, Hiroyuki I, Kyosan Y, Susumu K, Takayuki O (2010) Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy. J Magn Reson Imaging 28(3):372–379
Lecouvet F, Simon M, Tombal B, Jamart J, Bcvande B (2010) Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer. Eur Radiol 20(12):2973–2982
Lecouvet F (2016) Whole-body MR imaging: musculoskeletal applications. Radiology 279(2):345–365
Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71(1):81–92
Larbi A, Omoumi P, Pasoglou V, Michoux N, Triqueneaux P, Tombal B, Cyteval C, Lecouvet FEJER (2019) Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. Eur Radiol 29(8):4503–4513
Ramachandran V, Aslam S, Gary C (2007) MRI or bone scan or both for staging of prostate cancer? J Clin Oncol 25(36):5837
Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H et al (2016) Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5 T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 55(1):59–67
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N et al (2013) Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 105(14):1050–1058
Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P (2016) Evaluation of the 2015 gleason grade groups in a nationwide population-based cohort. Eur Urol 69(6):1135–1141
Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H (2015) Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5 T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 55(1):1–9
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Urol 175(2):564–564
Salvatori M, Rizzo A, Rovera G, Indovina L, Schillaci O (2019) Radiation dose in nuclear medicine: the hybrid imaging. Radiol Med 124(8):768–776
Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B et al (2019) Managing nonmetastatic castration-resistant prostate cancer. Eur Urol 75(2):285–293
Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, Machiels JP, Vande Berg B, Omoumi P, Tombal B (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62(1):68–75
Pasoglou V, Michoux N, Tombal B, Lecouvet F (2016) Optimising TNM staging of patients with prostate cancer using WB-MRI. J Belg Soc Radiol 100(1):101
Papageorgiou I, Dvorak J, Cosma I, Pfeil A, Teichgraeber U, Malich A (2020) Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer. Clin Transl Oncol 22(8):1321–1328
Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, Fogelman I (2010) The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 37(4):706–713
Cook GJ, Goh V (2018) Functional and hybrid imaging of bone metastases. J Bone Miner Res 33(6):961–972
Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, Omoumi P, Lecouvet F (2015) Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 275(1):155–166
Venkitaraman R, Cook GJ, Dearnaley DP, Parker CC, Khoo V, Eeles R, Huddart RA, Horwich A, Sohaib SA (2010) Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 53(3):241–247
This study is supported by National Natural Science Foundation Youth Project (Rui Chen, 81702514).
Conflict of interest
No conflicts of interest, financial or otherwise, are declared by the authors.
Ethics approval was obtained from the Ethics Review Board of Changhai Hospital.
Consent to participate
Informed consent was obtained from all patients included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Chen, R., Yang, Q., Chen, W. et al. Whole-body MRI-based multivariate prediction model in the assessment of bone metastasis in prostate cancer. World J Urol (2021). https://doi.org/10.1007/s00345-020-03571-8
- Whole-body MRI
- Prediction model
- Prostate cancer
- Bone metastasis